SS-31

SS-31, known in clinical development as elamipretide and formerly as Bendavia and MTP-131, is the most clinically advanced mitochondrial-targeted peptide in existence. Unlike most peptides in the longevity space that rely on animal studies and mechanistic speculation, SS-31 has progressed through multiple Phase II and Phase III human clinical trials for conditions including Barth syndrome, heart failure, and age-related mitochondrial dysfunction. It hasn't reached FDA approval yet, and its clinical journey has included setbacks, but the depth of its human data puts it in a fundamentally different category than research-only peptides.

This guide covers SS-31's unique mechanism of action — it concentrates inside mitochondria and interacts with cardiolipin, a lipid critical to mitochondrial energy production — the clinical trial results across multiple indications, what the data means for the broader aging and longevity conversation, and why this peptide represents both the promise and the difficulty of translating mitochondrial science into human therapeutics.

What Is SS-31?

SS-31 is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyltyrosine. It was developed by Hazel Szeto and Peter Bhatt at Weill Cornell Medical College as part of a series of Szeto-Schiller (SS) peptides designed to penetrate and concentrate within mitochondria.

The "SS" in SS-31 stands for Szeto-Schiller, after its co-developers. The peptide has undergone several name changes during clinical development:

• SS-31: Original research designation
• Bendavia: First clinical name (used by Stealth BioTherapeutics)
• MTP-131: Interim designation
• Elamipretide: Current generic pharmaceutical name

The commercial development has been led by Stealth BioTherapeutics, which has conducted multiple clinical trials and sought FDA approval for Barth syndrome.

Mitochondrial Targeting

SS-31's most distinctive property is its ability to concentrate inside mitochondria at 1,000-5,000 fold higher concentrations than in the surrounding cytoplasm. This selective accumulation is driven by the peptide's alternating aromatic-cationic motif (D-Arg and Lys provide positive charges; Dmt and Phe provide aromatic rings), which exploits the large negative membrane potential across the inner mitochondrial membrane.

This targeting is critically important because it means SS-31 achieves effective concentrations at its site of action (the inner mitochondrial membrane) at systemic doses that would be far too low to have effects if the peptide distributed uniformly throughout the cell. The mitochondrial concentration effect is SS-31's key pharmacological advantage.

How SS-31 Works: The Cardiolipin Connection

What Is Cardiolipin?

Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane. It has an unusual structure — four fatty acid chains instead of the typical two — that gives it distinctive biophysical properties essential for mitochondrial function.

Cardiolipin plays critical roles in:

• Electron transport chain organization: Cardiolipin provides the structural scaffold for respiratory chain supercomplexes, the molecular assemblies that perform oxidative phosphorylation
• Cytochrome c anchoring: Cardiolipin holds cytochrome c at the inner mitochondrial membrane surface, keeping it available for electron transport and preventing its release (which triggers apoptosis)
• Cristae formation: Cardiolipin is essential for the folded cristae structure of the inner mitochondrial membrane, which provides the surface area needed for ATP production
• ATP synthase function: Cardiolipin interacts directly with ATP synthase and contributes to its rotary catalytic mechanism

Cardiolipin and Aging

Cardiolipin undergoes significant changes with aging:

• Oxidative damage: Cardiolipin's four unsaturated fatty acid chains are highly susceptible to oxidation by reactive oxygen species (ROS). Aged mitochondria show increased cardiolipin oxidation, which disrupts respiratory chain organization and cytochrome c anchoring.
• Content decline: Total cardiolipin content decreases in some tissues with age.
• Fatty acid remodeling: The fatty acid composition of cardiolipin changes with age, shifting from the optimal linoleic acid-rich configuration to a more heterogeneous, less functional composition.

These cardiolipin changes are believed to be a significant contributor to age-related mitochondrial dysfunction — the declining energy production, increased ROS generation, and enhanced apoptotic sensitivity that characterize aging mitochondria.

SS-31's Cardiolipin Interaction

SS-31 binds selectively to cardiolipin in the inner mitochondrial membrane. This binding appears to:

Protect against oxidation: SS-31 reduces cardiolipin peroxidation, preserving the lipid's structural integrity and functional properties.

Optimize electron transport: By stabilizing cardiolipin-respiratory chain interactions, SS-31 improves electron transfer efficiency through the respiratory chain, reducing electron leak and ROS production while increasing ATP generation.

Stabilize cytochrome c: SS-31 enhances cardiolipin's anchoring of cytochrome c, reducing cytochrome c release and the downstream apoptotic signaling that contributes to tissue damage in ischemia-reperfusion injury, heart failure, and aging.

Restore cristae structure: In preclinical models, SS-31 has been shown to improve cristae morphology in aged and damaged mitochondria, partially restoring the structural organization needed for efficient energy production.

The net effect is that SS-31 acts as a mitochondrial "optimizer" — not by adding fuel or building new mitochondria, but by improving the efficiency and integrity of existing mitochondrial machinery through its interaction with cardiolipin.

Clinical Trial Data

Barth Syndrome: The Lead Indication

Barth syndrome is a rare X-linked genetic disorder caused by mutations in the tafazzin gene, which is essential for cardiolipin remodeling. Patients have abnormal cardiolipin composition, leading to severe mitochondrial dysfunction, cardiomyopathy, skeletal myopathy, and neutropenia. Barth syndrome is essentially a "cardiolipin disease" — making it the most mechanistically rational indication for a cardiolipin-targeting peptide like SS-31.

TAZA trial: The Phase II TAZA trial in Barth syndrome patients showed that elamipretide treatment improved 6-minute walk test distance and reduced cardiac biomarkers compared to baseline. The results were encouraging but the trial was small (given the rarity of the disease).

Phase III and FDA interactions: Stealth BioTherapeutics submitted a New Drug Application (NDA) for elamipretide in Barth syndrome. The FDA pathway has been complex — the agency has requested additional data and the approval process has been longer than anticipated. The rare disease context means clinical trials are necessarily small, making traditional statistical significance thresholds challenging to meet.

Heart Failure

SS-31 has been studied in patients with heart failure, where mitochondrial dysfunction is a significant contributor to impaired cardiac function.

PROGRESS trial: A Phase II trial in patients with heart failure with reduced ejection fraction evaluated elamipretide. Results showed improvements in some cardiac function parameters, though the primary endpoint results were mixed.

Ischemia-reperfusion injury: Earlier Phase II studies evaluated SS-31 (as Bendavia) in patients undergoing cardiac procedures where ischemia-reperfusion injury occurs (such as angioplasty for myocardial infarction). Results showed reduced biomarkers of cardiac damage in some studies, though clinical significance was debated.

Primary Mitochondrial Myopathy

Studies in patients with primary mitochondrial myopathies — genetic disorders affecting mitochondrial function — have evaluated elamipretide with mixed results. The heterogeneity of mitochondrial diseases makes clinical trial design challenging, and results have varied depending on the specific patient population and endpoints measured.

Age-Related Macular Degeneration (AMD)

A Phase I/II trial evaluated elamipretide in patients with geographic atrophy secondary to dry age-related macular degeneration — a condition involving RPE cell death linked to mitochondrial dysfunction. Early results showed potential for improving visual function in some patients.

Aging and Sarcopenia

Preclinical studies have shown that SS-31 improves muscle function, exercise capacity, and mitochondrial function in aged animals. These findings have generated interest in SS-31 for age-related sarcopenia and physical decline, though human trials specifically for aging indications are in early stages.

Dosing and Administration

Clinical Trial Dosing

In clinical trials, elamipretide has been administered via:

• Subcutaneous injection: Most common route in recent trials; typical doses of 4-40 mg daily
• Intravenous infusion: Used in earlier cardiac trials; single or short-course infusions
• Topical ophthalmic: Evaluated for AMD

The optimal dose for any indication is still being refined through clinical development.

Research/Off-Label Context

In the peptide therapy community, SS-31 dosing is extrapolated from clinical trial protocols and preclinical data:

• Commonly cited dose: 5-20 mg subcutaneously daily
• Duration: Variable, often in 4-8 week cycles
• Timing: Not highly dependent on food timing (unlike GH secretagogues)

These doses are not clinically validated for anti-aging applications. They represent extrapolation from therapeutic trial dosing.

Side Effects and Safety

Clinical Trial Safety Data

The clinical trial safety database for elamipretide is the most extensive of any mitochondrial-targeted peptide:

• Injection site reactions: The most common adverse event — redness, pain, or nodules at injection sites (10-25%)
• Headache: Reported in some trials (5-15%)
• Nausea: Occasional, generally mild (3-8%)
• Fatigue: Reported by some patients, though difficult to distinguish from underlying disease effects
• Hypersensitivity: Rare reports of allergic-type reactions

Overall, the safety profile has been described as generally favorable across clinical trials, with no major safety signals emerging from the accumulated data. This is one of SS-31's strengths relative to other mitochondrial-targeting approaches — it appears to improve mitochondrial function without the toxicity concerns associated with many mitochondrial-targeted compounds.

Theoretical Considerations

Dependency concern: If SS-31 optimizes mitochondrial function through continuous cardiolipin interaction, discontinuation might theoretically result in return to baseline mitochondrial dysfunction. This is not a "withdrawal" effect but rather the absence of ongoing benefit.

Interaction with mitochondrial-toxic drugs: SS-31's mitochondrial effects could theoretically interact with drugs that affect mitochondrial function (certain antibiotics, statins, metformin). No significant drug interactions have been reported in clinical trials, but the theoretical concern exists.

SS-31 vs. Other Longevity Peptides

vs. MOTS-c

MOTS-c is produced by mitochondria and signals outward (retrograde signaling). SS-31 comes from outside and targets mitochondria (anterograde targeting). They address mitochondrial function from opposite directions and could theoretically be complementary. SS-31 has substantially more human clinical data.

vs. NAD+ Therapy

NAD+ therapy provides the coenzyme substrate that mitochondria need for electron transport. SS-31 optimizes the structural organization of the electron transport chain itself. They address different aspects of mitochondrial energy production — substrate supply (NAD+) vs. machinery efficiency (SS-31).

vs. Epitalon

Epitalon targets a different aging axis entirely (telomerase). SS-31 has vastly superior evidence quality — multiple Phase II/III trials from independent research groups and a defined molecular mechanism, compared to epitalon's single-group data and unverified telomerase claims.

vs. Humanin

Humanin is a mitochondrial-derived peptide like MOTS-c, focused on anti-apoptotic and neuroprotective effects. SS-31 targets mitochondrial bioenergetics through cardiolipin. Different mechanisms, potentially complementary, with SS-31 having more advanced clinical development.

Who Should Consider SS-31

Evidence-Supported Candidates

• Patients with Barth syndrome: The most mechanistically rational indication, with active clinical development
• Patients with primary mitochondrial diseases: Under clinical investigation
• Heart failure patients: Based on early clinical data, though the evidence is still developing

Speculative/Off-Label Interest

• Age-related mitochondrial decline: The preclinical rationale is strong but human anti-aging trials are in early stages
• Age-related sarcopenia: Promising preclinical data, awaiting human validation
• AMD patients: Early clinical data is intriguing

Who Should Avoid SS-31

• Those expecting immediate, dramatic anti-aging effects (the evidence supports modest mitochondrial optimization, not dramatic reversal)
• Patients unwilling to accept the uncertainty of an unapproved therapeutic
• Anyone with known hypersensitivity to the peptide or its formulation components

The Bottom Line

SS-31 is the most scientifically rigorous mitochondrial peptide in development. Its mechanism — cardiolipin binding that optimizes electron transport chain organization — is clearly defined, independently validated, and mechanistically sound. Its clinical trial program, while not yet resulting in FDA approval, has generated the most extensive human safety and efficacy data of any longevity-oriented peptide.

The challenge is that clinical trials have produced mixed results — encouraging in some endpoints, disappointing in others — reflecting the general difficulty of translating mitochondrial science into measurable clinical outcomes. Mitochondrial dysfunction is real and important in aging and disease, but proving that correcting it produces clinical benefit that patients and regulators can agree on is harder than the preclinical data suggests.

SS-31 represents the best of mitochondrial medicine: careful science, defined mechanism, rigorous clinical development. It also represents the challenge: even with all of that rigor, proving clinical benefit is difficult. For the longevity field, SS-31's ongoing clinical program is one of the most important stories to watch.

For the broader longevity landscape, see our profiles on MOTS-c, humanin, epitalon, FOXO4-DRI, and our NAD+ IV therapy guide.